A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema
NCT ID: NCT07086339
Last Updated: 2025-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
20 participants
INTERVENTIONAL
2025-09-30
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
NCT07119229
Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema
NCT05949645
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
NCT01908933
First in Human Study to Assess an Implant to Treat Severe Emphysema
NCT05854550
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
One or two procedures involving placement of up to 10 IAB implants in one or both lungs
Implantable pulmonary stent
Implantable polymer based pulmonary stent for severe COPD/emphysema
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Implantable pulmonary stent
Implantable polymer based pulmonary stent for severe COPD/emphysema
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of COPD/emphysema
3. At least 22-years of age
4. 18 ≤ BMI ≤ 32
5. 6-minute walk Distance of between 100 - and 400 meters
6. Stable disease with less than 10-mg prednisone (or equivalent) daily
7. Non-smoking for 4-months prior to screening interview (this includes tobacco, vaping, marijuana, etc.).
8. FEV1 between 15% and 45% of predicted value at baseline exam
9. FEV1/FVC \<70%
10. Subject has ≥25% emphysema destruction score in each lung defined by areas of low attenuation less than -950 HU, as determined by CT core lab.
11. Subject has homogeneous or heterogeneous emphysema, and at least one lung has a 15% difference between upper and lower lobes in emphysema destruction score less than -950 HU, as determined by CT core lab.
12. RV \> 175% of predicted value.
13. mMRC score ≥ 2
Exclusion Criteria
2. α-1 Antitrypsin deficiency
3. Women of child-bearing potential
4. More than 2 COPD exacerbation episodes requiring hospitalization in the last year prior to screening
5. Any COPD exacerbations requiring hospitalization within 6-weeks of planned intervention
6. Two or more instances of pneumonia episodes requiring hospitalization in the last year prior to screening
7. Clinically significant mucus production or chronic bronchitis
8. Myocardial Infarction or unstable / uncontrolled congestive heart failure within 6-months of screening
9. Prior lung transplant, LVRS, bullectomy, lobectomy or endoscopic lung volume reduction (ELVR)
10. Clinically significant bronchiectasis
11. Unable to safely discontinue anti-coagulants or platelet activity inhibitors for 7-days
12. Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure \>45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram
13. Suspected malignant pulmonary nodule or other lung cancer
14. HRCT collected per CT scanning protocol within the last 6 months of screening date and evaluated by clinical site personnel using 3D segmentation software shows:
* Large bullae encompassing greater than 30% of either lung
* Insufficient landmarks to evaluate the CT study using the software as it is intended
* All lobes are less than 25% parenchyma diseased (\< -950 HU).
15. Any cardiac comorbidity which the PI believes would compromise the safety of the patient after an IAB implant
16. TLC \< 100% predicted at screening
17. DLCO \< 15% or \> 50% of predicted value at screening
18. PaCO2 \> 50 mm Hg at screening
19. PaO2 \< 45 mm Hg in room air at screening
20. Plasma cotinine level \> 13.7 ng/ml or carboxyhemoglobin (arterial or ear lobe capillary) \>2.5% at screening.
21. Current diagnosis of substance abuse disorder.
22. Current diagnosis of any of the following: Major Depressive Disorder (MDD), Schizoaffective Disorder, Schizophrenia, Borderline Personality Disorder, Bipolar Disorder
23. Any other conditions, which, in the opinion of the Investigator, would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.
22 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pulmair Medical, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IAB3-CIP-v01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.